ERBB2 and cancer: Several HER2-based epitopes have been evaluated as phage-based cancer vaccines in pre-clinical research studies, such as AE37 (Ii-Key/HER-2/neu 776–790), H-2kd-restricted CTL, Δ16HER2 exposed, and peptide GP2 [257,258,259,260].